1.68
+0.04(+2.44%)
Currency In USD
| Previous Close | 1.64 |
| Open | 1.65 |
| Day High | 1.69 |
| Day Low | 1.63 |
| 52-Week High | 2.8 |
| 52-Week Low | 1.11 |
| Volume | 674,358 |
| Average Volume | 3.08M |
| Market Cap | 447.12M |
| PE | -2.02 |
| EPS | -0.83 |
| Moving Average 50 Days | 1.49 |
| Moving Average 200 Days | 1.72 |
| Change | 0.04 |
If you invested $1000 in Autolus Therapeutics plc (AUTL) since IPO date, it would be worth $67.2 as of December 25, 2025 at a share price of $1.68. Whereas If you bought $1000 worth of Autolus Therapeutics plc (AUTL) shares 5 years ago, it would be worth $190.48 as of December 25, 2025 at a share price of $1.68.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire Inc.
Dec 08, 2025 9:05 PM GMT
Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep B-cell depletion after infusion, suggesting an immune
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire Inc.
Dec 08, 2025 1:35 PM GMT
Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (IC
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today